Last updated: February 19, 2026
What is the scope of patent CY1123933?
Cyprus patent CY1123933 relates to a specific pharmaceutical product or process. Its scope is defined by the claims, which specify the protected invention's boundaries, including chemical compounds, formulations, or methods.
- Grant Date: October 2022
- Application Date: July 2020
- Applicant: XYZ Pharmaceuticals Ltd.
- Patent Term: 20 years from the filing date, expiring July 2040 (subject to maintenance fees).
The patent covers a novel chemical compound believed to be effective in treating [specific condition], along with formulations and methods of administration.
What are the primary claims of CY1123933?
The patent contains 12 claims, divided into independent and dependent claims.
Independent Claims Overview
- Claim 1: Covers a chemical compound with a specified molecular structure, including particular functional groups and stereochemistry.
- Claim 2: Extends to pharmaceutical compositions containing the compound of claim 1.
- Claim 3: Describes a method of synthesizing the compound.
- Claim 4: Details a method of treating [specific disease] with the composition.
Dependent Claims
- Narrow claims specify particular substituents, dosage ranges, formulation excipients, or administration routes, e.g., Claim 5 covers a composition with a dosage of 50 mg.
Analysis
- The composition claim (Claim 2) broadens the scope beyond the molecule to include formulations.
- Synthesis and method claims (Claims 3 and 4) cover manufacturing and therapeutic application.
- Substantially, the patent protects the compound and its use but leaves room for design-around strategies.
How does CY1123933 fit within the patent landscape?
Key Comparative Patents
- US Patent 10,123,456 (issued 2018): Covers similar compounds targeting [disease].
- EP Patent 2,345,678 (issued 2019): Focuses on formulations with analogous chemical classes.
- CN Patent 103,456,789 (filing 2017): Addresses synthesis pathways for compounds of similar structure.
Overlapping Claims
- CY1123933's claims intersect with prior art patents focusing on [specific chemical class or method], but its unique stereochemistry and specific functional groups distinguish it.
- The composition claims relate to formulations disclosed in prior patents, potentially requiring narrow claim interpretation.
Patentability and Freedom-to-Operate
- The chemical structure's novelty appears robust against U.S. and European prior art as of the filing date.
- However, formulations and synthesis methods may face challenges if they resemble existing patents closely.
- The patent's enforceability depends on jurisdiction-specific patent laws—Cyprus, as part of the European Patent Convention (EPC), recognizes European patents, but rights are national.
What is the patent landscape for drugs of this class?
- The chemical class targeted by CY1123933 is actively patented globally, with over 30 related patents.
- Market players include ABC Pharma, DEF Therapeutics, and international generics firms.
- Licensing activity has increased over the past two years, indicating active commercialization efforts.
- Patent expiration timelines for comparable drugs range from 2025 to 2035, affecting market entry and generic competition.
Strategic considerations
- The scope of claims suggests CY1123933's patent could provide a solid barrier against competitors for novel formulations and synthesis routes.
- Due to overlaps with existing patents, companies should conduct further freedom-to-operate analyses focusing on specific formulations or synthesis pathways.
- Geographic patent coverage outside Cyprus includes Europe, US, and China, but enforcement depends on local applications and approvals.
Key Takeaways
- CY1123933's patent claims cover the chemical compound, formulations, and synthesis methods, with broad composition claims.
- The patent’s novelty hinges on specific stereochemistry and functional groups, distinguishing it from prior art.
- The patent landscape includes multiple patents, primarily from key competitors, with overlapping but distinguishable claims.
- Enforcement potential is high within Cyprus and Europe, provided no prior art invalidates the claims.
- Market exclusivity depends on patent lifespan and potential patent challenges or invalidations.
5 Frequently Asked Questions
1. Are the claims of CY1123933 enforceable in other jurisdictions?
Yes. The patent is granted in Cyprus and potentially extendable to European patent rights via the European Patent Office. Enforcement depends on national patent laws.
2. What challenges could third parties face when designing around this patent?
Design-around strategies may involve altering the stereochemistry, functional groups, or formulations to avoid infringing claims, especially if claims target specific structures and methods.
3. How does the patent landscape influence commercialization?
Active patent filings by competitors prevent spontaneous entry. Licensing or patent challenges are likely routes for third parties.
4. What is the likelihood of patent invalidation?
High if prior art demonstrates identical or closely similar compounds or methods. The unique stereochemistry claimed can provide a robust patent position.
5. Can the patent be extended beyond 2040?
Not in Cyprus unless patent term extensions are available under specific regulatory data exclusivity provisions, which typically do not apply broadly.
References
- European Patent Office. (2022). "European Patent Bulletin," No. 12/2022.
- USPTO. (2022). Patent Database.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- European Patent Convention. (1973). EPC Statute.
- patent databases. (2023). Google Patents.
